Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Daniel Siri"'
Autor:
Jonathan D Akikusa, Francesca Bovis, Graciela Espada, Christoph Rietschel, Elżbieta Smolewska, Yukiko Kimura, Alina Boteanu, Diane E. Brown, Daniel Siri, Fabrizio De Benedetti, Nicolino Ruperto, Heinrike Schmeling, Bin Huang, Chen Chen, Daniel J. Lovell, Rik Joos, Hermine I. Brunner, Alberto Martini, Jeffrey Chaitow
Publikováno v:
Arthritis Care & Research. 73:1264-1274
OBJECTIVE To evaluate changes in health-related quality of life (HRQoL) and disability in children with systemic juvenile idiopathic arthritis (JIA) or polyarticular JIA treated with tocilizumab. METHODS Secondary analyses of two double-blind, placeb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84257a021921d88091d8a389b5dfb63d
https://doi.org/10.1002/acr.24384
https://doi.org/10.1002/acr.24384
Autor:
Eliseo Gonzalez, Eduardo Scheines, Horacio Venarotti, María de los Ángeles Correa, Maria Alicia Lazaro, Jorge Velasco Zamora, Lucas Cordeiro, Andrea Federico, Rodolfo Pardo Hidalgo, Eduardo Mysler, Alberto Spindler, Daniel Siri, Ezequiel Klimovsky, Nestor Lago, Ingrid Strusberg, Patricio Tate, Gustavo Citera
Publikováno v:
Journal of clinical rheumatology : practical reports on rheumaticmusculoskeletal diseases. 27(6S)
Background Enerceptan (EtaBS) has been developed as a proposed biosimilar of etanercept. Methods This randomized, multicenter, evaluator-blinded, noninferiority study conducted in Argentina included adults with active, moderate, and severe rheumatoid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ab111704a45f77bbbd2acc4390feb73
https://pubmed.ncbi.nlm.nih.gov/33337815
https://pubmed.ncbi.nlm.nih.gov/33337815
Autor:
Jeffrey Chaitow, Rik Joos, Nicolino Ruperto, Graciela Espada, Yukiko Kimura, Diane Brown, Elżbieta Smolewska, Daniel J. Lovell, Chen Chen, Bin Huang, Fabrizio De Benedetti, Heinrike Schmeling, Daniel Siri, Jonathan D Akikusa, Gámir Gámir Maria Luz, Christoph Rietschel, Hermine I. Brunner, Alberto Martini
Publikováno v:
Paediatric rheumatology.
Background Tocilizumab (TCZ) intravenous (IV) formulation was approved for the treatment of patients with systemic juvenile idiopathic arthritis (sJIA) based on the results of a large phase 3 clinical trial. Physical function, measured by the Childho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92d3a86aea74b1771189dabba83406d4
https://doi.org/10.1136/annrheumdis-2019-eular.3392
https://doi.org/10.1136/annrheumdis-2019-eular.3392
Autor:
Thasia G. Woodworth, Juan J. Gomez-Reino, Graeme Jones, Mark C. Genovese, Jieruo Gu, Matija Tomšič, Daniel Siri, Mitchell B. Lowenstein, Emma Alecock, Armando Calvo, Anthony Sebba
Publikováno v:
Annals of the Rheumatic Diseases
Background:The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis.Objective:To evaluate through the AMBITION study the efficacy and safety of tocilizumab monother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ee2569a6f2df08893cf7372acf14a97
https://pubmed.ncbi.nlm.nih.gov/19297346
https://pubmed.ncbi.nlm.nih.gov/19297346
Autor:
Eduardo Mysler, J. P. Solé, A. Alvarellos, A. Eimon, L. Najun Dubos, J. Velasco Zamora, A. Borgia, R. Garcia Salinas, Daniel Siri, C. Wiederhold, F. Sommerfleck, L. Re
Publikováno v:
Annals of the Rheumatic Diseases. 72:A411.3-A412
Background In RA patients, where biological therapy is needed, combination therapy (CT) with a biological agent plus MTX remains the standard of care. However, in some scenarios (i.e. DMARD intolerance, non-compliance) BMT appears as a therapeutic op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7764cb29a7679018cc616bda9697ba7
https://doi.org/10.1136/annrheumdis-2013-eular.1250
https://doi.org/10.1136/annrheumdis-2013-eular.1250